Nalaganje...

Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial

IMPORTANCE: Response patterns with immunotherapy may differ from those of other treatments. This warrants further investigation because some patients may benefit from continued immunotherapy beyond Response Evaluation Criteria in Solid Tumors (RECIST)-defined first progression. OBJECTIVE: To evaluat...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:JAMA Oncol
Main Authors: George, Saby, Motzer, Robert J., Hammers, Hans J., Redman, Bruce G., Kuzel, Timothy M., Tykodi, Scott S., Plimack, Elizabeth R., Jiang, Joel, Waxman, Ian M., Rini, Brian I.
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5568541/
https://ncbi.nlm.nih.gov/pubmed/27243803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2016.0775
Oznake: Označite
Brez oznak, prvi označite!